Endoscopic Evaluation of Gastro‑Esophageal Reflux Disease (GERD)

1. Frequency of Endoscopic Findings in GERD

• Only 15–50 % of patients with GERD demonstrate visible mucosal abnormalities on upper endoscopy; the remaining 50–85 % have non‑erosive reflux disease (normal‑appearing mucosa despite reflux symptoms). 1

2. Endoscopic Lesions That May Be Detected

2.1. Erosive Esophagitis

• Endoscopic grading follows the Los Angeles classification (grades A–D); grades B–D are considered severe erosive disease. 2

2.2. Esophageal Strictures

• Chronic scarring can produce luminal narrowing (stricture) that is visible on endoscopy. 3

2.3. Barrett’s Esophagus

• Metaplastic columnar epithelium replaces normal squamous lining in approximately 10 % of individuals with long‑standing GERD. 4

3. Indications for Upper Endoscopy (American College of Physicians)

3.1. Absolute Indications – Endoscopy Required Immediately

3.2. Conditional (Consider) Indications – Endoscopy Based on Individual Risk

• Screening for Barrett’s esophagus / adenocarcinoma – Men > 50 years with chronic GERD > 5 years plus additional risk factors (nocturnal reflux, hiatal hernia, elevated BMI, tobacco use, central obesity). Shared decision‑making recommended. 3
• Surveillance of known Barrett’s esophagus – Endoscopic monitoring every 3–5 years when no dysplasia is present; more frequent intervals when dysplasia is detected. 3

3.3. Situations Where Endoscopy Is Not Indicated

• Typical GERD symptoms without alarm features – Empiric PPI trial for 4–8 weeks is preferred. 3
• Routine screening in women of any age or men < 50 years – Very low incidence of esophageal cancer. 3
• After a negative screening endoscopy (no Barrett’s, no cancer) – Repeat endoscopy is unnecessary. 3
• Asymptomatic patients with a prior stricture – Endoscopy should be symptom‑driven. 3

4. Diagnostic Pitfalls

• A normal endoscopic exam does not exclude GERD; diagnosis relies on clinical symptoms and response to PPI therapy. 1

5. Practical Management Algorithm (ACP Guidance)

• If alarm symptoms are present → perform upper endoscopy immediately. 3

• If no alarm symptoms → start twice‑daily PPI for 4–8 weeks. 3

• Symptom resolution → continue PPI at lowest effective dose; no endoscopy needed. 3

• Persistent symptoms → schedule upper endoscopy. 3

• Severe erosive esophagitis (LA B–D) → repeat endoscopy after 2 months of PPI to verify healing and rule out Barrett’s. 2
• Barrett’s esophagus without dysplasia → surveillance endoscopy every 3–5 years. 3

• Barrett’s esophagus with dysplasia → more frequent surveillance (intervals < 3 years). 3

• Men > 50 years with chronic GERD > 5 years and additional risk factors may undergo a one‑time screening endoscopy after shared decision‑making; a negative result obviates further screening. 3

All statements are based on recommendations from the *American College of Physicians* and are supported by the cited literature. Strength of evidence was not explicitly reported in the source material.

Indications for Endoscopy in GERD Management

Absolute Indications for Endoscopy

• The American College of Physicians recommends performing endoscopy immediately in any patient with heartburn plus alarm symptoms, such as dysphagia, gastrointestinal bleeding, anemia, or recurrent vomiting, regardless of age or gender 5, 6, 7
• Endoscopy is indicated when typical GERD symptoms persist despite 4-8 weeks of twice-daily PPI therapy, representing true refractory symptoms requiring objective evaluation 5, 6, 7
• After diagnosing severe erosive esophagitis, the American Gastroenterological Association recommends performing follow-up endoscopy after 2 months of PPI therapy to assess healing and rule out Barrett's esophagus 5, 8
• The risk of developing stricture, Barrett's, or cancer after healing is only 1.9%, 0%, and 0.1% over 7 years respectively, according to the American College of Gastroenterology 8

Conditional Indications

• The American College of Gastroenterology recommends considering screening endoscopy in men over 50 years old with chronic GERD (over 5 years duration) plus multiple additional risk factors, such as nocturnal reflux symptoms, hiatal hernia, elevated body mass index, tobacco use, or intra-abdominal fat distribution 5, 6, 7, 9
• For patients with known Barrett's esophagus without dysplasia, the American Society for Gastrointestinal Endoscopy recommends surveillance intervals of 3-5 years 5, 8
• More frequent surveillance is indicated for patients with dysplasia due to higher cancer progression risk, according to the American College of Gastroenterology 5, 9

Important Considerations

• Screening should not be routinely performed in women of any age or men under 50 years, as cancer incidence is very low in these populations, according to the American Cancer Society 9
• Life-limiting comorbidities should factor into the screening decision, as recommended by the American Geriatrics Society 7
• If initial screening is negative, recurrent periodic endoscopy is not indicated, according to the American College of Physicians 7, 9